What will investors typically ask for or expect during science-tech due diligence? (8/8) It's the final part of our "How to Prepare for Science-Tech Due Diligence" series! Let's dive into the final areas. → Regulatory & Policy Environment Investors may assess whether there are favorable policies, subsidies, or standards supporting your technology. They’ll also want to understand how regulatory approvals and safety certifications could affect your go-to-market timeline, especially in highly regulated sectors like healthcare, energy, and chemicals. → Exit to Strategic Buyers Investors may also explore the potential for an exit via acquisition by strategic buyers, specifically where this is a viable alternative to an IPO. They will evaluate how your technology fits into a corporate portfolio and whether there is interest in acquiring your company. Understanding the acquisition landscape and competitive positioning can provide a clearer path to exit. For a full overview of the areas that will come under scrutiny during an investor's science-tech due diligence process, download the free guide: https://lnkd.in/dQPuVxpG Want a headstart in investor readiness? Get hands-on support from leading science-tech and industry advisors. Schedule an intro: https://lnkd.in/eQevQChq #startup #funding #fundraising #vc #sciencetech
Deepsense’s Post
More Relevant Posts
-
💡 Biotech’s New Reality: A Shift Toward M&A 💡 As venture funding tightens and IPOs stall, the biotech sector is pivoting to M&A for growth. Many companies are finding that strategic partnerships and acquisitions offer faster paths to scale and capital efficiency. This shift could bring a wave of consolidation, where cash-rich firms acquire innovative startups, driving fresh opportunities and creating new synergies. For investors, it’s a unique moment to engage with companies prioritizing strategic alliances over independent scaling. Exciting times ahead in biotech! #Biotech #MergersAndAcquisitions #LifeSciences
-
Traditional VC follows a linear path: source, assess, win, invest, support, exit. Avra Capital is turning this model on its head. See how they're reordering venture capital's traditional sequencing: Our latest piece offers an unprecedented look into this innovative approach. Read the full story: https://lnkd.in/eAzsar5e
-
-
The biotech industry is seeing a resurgence in venture mega-rounds, with deals of $100 million or more becoming increasingly common. Despite fewer overall deals and less venture capital flowing into biotech, these large rounds are pushing the sector to approach the record totals of 2021. According to recent data, venture investors put $15.3 billion into 351 biotech financings in the first half of this year, compared to $36.6 billion through 845 rounds in all of 2021 (SVB). For biotech companies navigating these evolving financial landscapes, strategic foresight and careful planning are key to sustaining growth. #BiotechFunding #VentureCapital #MegaRounds #BiotechIndustry #StrategicGrowth #DavidHaigAssociates
-
-
In a world where technology is advancing at lightning speed and market dynamics are constantly shifting, corporate venturing and venture capital (VC) have become essential tools for companies looking to stay competitive. At hea Global, we explore the evolving landscape of corporate venturing, identifying emerging trends and innovative strategies that can significantly influence how companies grow and adapt. Dive into the latest insights on how to navigate this rapidly changing environment and drive your organization's innovation forward. https://hea.global/ #globalinnovation #businessstrategy #thoughtleadership #innovationecosystem #digitalfuture #sustainablegrowth #entrepreneurmindset #nextgenbusiness #globalleaders #strategicinnovation
-
Fascinating insights from BioPharma Dive on the shift in venture #investments towards clinical-stage firms over preclinical ones. Promising signs of stability and growth are emerging in the #biotech industry as we progress through 2024. With less investment in preclinical firms, could there be a slowdown in the development of early-stage innovations? Nevertheless, the increased focus on clinical-stage companies could lead to more efficient allocation of resources and faster translation of research into tangible products!
Venture investment into U.S. biotechs is back at pre-COVID levels. But firms seem more selective in the companies they favor, and some are looking toward M&A rather than IPOs for an exit.
-
🚀 The Power of Consistency in Corporate Venture Capital 🚀 🎙 In a recent conversation, Itziar Estevez, Growth Partner at Iris Capital and former investor at Siemens' CVC arm Next47, shed light on the importance of consistency in corporate venture capital. "What made Siemens stand out was their strong conviction in venture capital, consistently investing across economic cycles." This long-term perspective, backed by top management, allowed Siemens to capitalize on large successes that more than made up for any shortfalls along the way. 💼 The key takeaway? For Corporate VC to truly succeed, it’s crucial for leadership to think beyond quarterly results and focus on long-term innovation. 📊 #CorporateVentureCapital #CVC #LongTermInvesting #Innovation #VentureCapital #SiemensCVC #IrisCapital #ItziarEstevez #BusinessGrowth #StartupInvesting #Next47 #InvestmentStrategies #CorporateGrowth #WhtasInStoreShow #BusinessResilience #EconomicCycles #SuccessStories #Innovation #BusinessInsights
-
In a world where technology is advancing at lightning speed and market dynamics are constantly shifting, corporate venturing and venture capital (VC) have become essential tools for companies looking to stay competitive. At hea Global, we explore the evolving landscape of corporate venturing, identifying emerging trends and innovative strategies that can significantly influence how companies grow and adapt. Dive into the latest insights on how to navigate this rapidly changing environment and drive your organization's innovation forward. https://hea.global/ #globalinnovation #businessstrategy #thoughtleadership #innovationecosystem #digitalfuture #sustainablegrowth #entrepreneurmindset #nextgenbusiness #globalleaders #strategicinnovation
-
Private capital is the lifeblood of innovation! Emerging companies are at the forefront of some of the most groundbreaking and disruptive developments we've seen in decades. With strong teams, unique Intellectual Property, and access to growing markets, these companies are poised to lead the next wave of innovation. But what is the missing link that truly enables them to scale? It's the infusion of private capital. Investors—who are willing to take on risk—are essential in providing the fuel that powers these companies to new heights. By supporting the next generation of innovators, private capital isn't just funding companies; it’s driving the future of our economy. The companies backed by these investments will go on to shape industries, create jobs, and sustain the growth of our innovation ecosystem. The question for investors today: Are you ready to help build the next big thing? #PrivateCapital #Innovation #EmergingCompanies #VentureCapital Transpera Technologies Inc. AND Capital Ventures
-
-
To thrive in today's increasingly-selective #funding landscape, Biotech must consider the criteria behind venture capital investments. Based on our survey with 50+ prominent venture capitalists, we have identified 8 criteria that shape how biopharma-focused VCs evaluate potential #Biotech funding in 2024. Read full article ➡️ https://lnkd.in/dhj496Ye
-
